Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs

International Journal of STD and AIDS

Volumn 12, Issue 5, 2001, Pages 324-328

  Pradier, Christian ^a,b   Carrieri, Patrizia ^b   Bentz, Laurence ^a   Spire, Bruno ^b   Dellamonica, Pierre ^a   Moreau, Joel ^c   Moatti, Jean Paul ^b,d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b INSERM   (France)

^c Hopital Felix Houphouet Boigny   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Adherence; Highly active antiretroviral treatment; Immunological and virological success; Injection drug use

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; SAQUINAVIR;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034997730     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011923165     Document Type: Article

References (29)

1. 1 Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665
2. 2 Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-7
3. 3 Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patient: a prospective cohort study. Lancet 1999;353:863-8
4. 4 Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor: discrepancy between results in an observational study. AIDS 2000;14:141-9
5. 5 Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12:2161-7
6. 6 Descamps D, Flandre P, Calvez V, et al. (Agence Nationale de Recherches sur le SIDA 072) Study Team. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000;283:205-11
7. 7 Hecht F, Grant R, Petropoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-11
8. 8 Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
9. 9 Bonuck K, Amo P. Social and medical factors affecting hospital discharge of persons with HIV/AIDS. J Epidemiol Comm Health 1997;22:225-32
10. 10 Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000;26:195-205
11. 11 Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47:1-83
12. 12 Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-16
13. 13 Casado JL, Perez Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998;12:F131-5
14. 14 Janz N, Becker M. The health belief model: a decade later. Health Educ Quart 1984;11:1-47
15. 15 Muma R, Ross M, Parcel G, Pollard R. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7:439-47
16. 16 Singh N, Squier C, Sivek C, Wagener M, Nguyen M, Yu V. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9
17. 17 Bangsberg D, Hecht F, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66
18. 18 Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999;13:1099-107
19. 19 Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95
20. 20 Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74
21. 21 Senak M. Predicting antiviral compliance: physician's responsibilities vs patients' rights. J Intl Assn Phys in AIDS Care 1997;3:45-8
22. 22 Stewart G. Adherence to antiretroviral therapies. In: Van Praag E, Fernyak S, Katz A, eds. The Implications of Antiretroviral Treatments. Informal Consultation. Geneva: WHO/UNAIDS, 1997:35-50
23. 23 Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J AIDS 1999;21;114-19
24. 24 Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Comm Health 1999;53:4-8
25. 25 Lerner B, Gulick R, Dubler N. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998;129:573-8
26. 26 Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30:S171-6
27. 27 Spire B, Souville M. Drug-resistant genotyping in HIV-1 therapy. Lancet 1999;354:1121
28. 28 Deeks SG, Barbour JD, Martin JN, Grant RM. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy (Abstract 236). Programs and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000
29. 29 Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp Med Biol 1999;458:175-82